NCT04840004View on ClinicalTrials.gov

Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non Small Cell Lung CancerAdvanced CancerRefractory Cancer
Interventions
DRUG

PVT-1

Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.

Trial Locations (4)

Unknown

RECRUITING

Baskent University, Adana

RECRUITING

Gazi University, Ankara

RECRUITING

Yeditepe University Hospital, Istanbul

RECRUITING

"19 May, s University"

All Listed Sponsors
collaborator

ECONiX Araştırma Analiz ve Danışmanlık A.Ş.

INDUSTRY

lead

PlusVitech S.L.

OTHER